Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-ART: Trabectedin/Olaparib in HRR-deficient solid tumors
NCT03127215Phase 2Completed
- Sponsor
- National Center for Tumor Diseases
- Start
- Oct 2018
- Primary completion
- Dec 2023
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of olaparib and trabectedin in solid tumor (2 arms), sponsored by National Center for Tumor Diseases. Primary endpoint: Disease Control Rate at 16 weeks. Started Oct 2018; status: completed.
02
Drugs
olaparibtrabectedin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03127215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127215.